 The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12 yesterday, while it is down 14 in the last five trading days. In comparison, the broader SP500 index. 